The South Asian nation has agreed a more flexible exchange rate to help unlock $1.3bn of funds.

A core product for Type 2 diabetes is expected to commercially launch in mainland China by the end of this year, subject to regulatory approval; CICC led the transaction.

CICC is looking to strengthen ties between China and the Gulf region; meanwhile, a former MD at Standard Chartered, Kapil Jobanputra, has become managing partner of real asset firm Elaeo Partners.

The US giant will pay the money upfront for distribution rights for SSGJ-707 outside of China; the deal could be worth up to $4.8bn and Pfizer will also invest $100m into the HKEX listed firm.

The dual listing will help keep momentum in Hong Kong's equity markets, with the majority of the $4.5bn proceeds raised by the Shenzhen based global EV player set to help build a factory in Hungary; a greenshoe option takes the raising to $5.2bn.

Shilpa Gulrajani, DBS' head of sustainable finance, institutional banking, offered her thoughts on how capital markets are aligning with the region’s transition needs, including green loans and blended finance, on the sidelines of Ecosperity Week.

The issuance from the Hong Kong conglomerate, formerly known as NWS Holdings, was to finance the redemption of its outstanding offshore capital securities by its subsidiary.

The Hong Kong-headquartered Asian life insurer, backed by billionaire Richard Li, has made several similar filings in recent years without triggering an IPO.

Standard Chartered is providing full FX services with more services expected in Q4; FA understands that FalconX will partner with more banks soon.

Exports grew 15% in Q1, however there is expected to be a slowdown moving forward as tariffs bite, the baht remains strong and tourism faces headwinds.